Soheil Jahangiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Soheil Jahangiri has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Mark David Minden
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
118 shared publications - John E. Dick
Department of Molecular Genetics, University of Toronto
116 shared publications - Amanda Tajik
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
115 shared publications - Ana Vujovic
Division of Hematology, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado
115 shared publications - Ava Keyvani Chahi
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada
115 shared publications - Brian A. Yee
Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, USA
115 shared publications
Latest Publications
- Open Access
- 20 April 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (10) , 1277-1291
IFNγ Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy
Cancer survivors experience long-term skeletal and hematopoietic complications that limit quality of life following chemotherapy (CTX), yet the mechanisms underlying these defects remain incompletely understood. Using a murine model of doxorubicin (DOX)-based leukemia induction therapy, we show that CTX induces inflammatory remodeling of the bone marrow (BM) niche. DOX treatment resulted in loss of arteriolar vasculature, blockade of mesenchymal stromal cell (MSC) differentiation, trabecular bone loss, and reduced niche capacity to maintain hematopoietic stem cells (HSCs). These defects were accompanied by aberrant immune activation within the BM, marked by increased interferon-γ (IFNγ) production by CD8⁺ T cells. Inhibition of IFNγ signaling partially restored arteriolar vessels and adipogenic differentiation. Moreover, combined IFNγ blockade and deferoxamine mesylate (DFM), which promotes vascular recovery, attenuated chemotherapy-associated skeletal damage. Consistent with these findings, paired BM samples collected at diagnosis and post-CTX from leukemia patients exhibited altered MSC lineage priming, upregulation of inflammatory pathways, and expansion of BM CD8⁺ memory T cells after treatment. Together, these findings implicate IFNγ-driven chronic inflammatory remodeling as a central mechanism of CTX-associated BM niche dysfunction and pinpoints inflammatory signaling as a potential target to preserve BM function and long-term tissue integrity.
- 20 April 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (10) , 1277-1291
Open AccessIFNγ Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy
Cancer survivors experience long-term skeletal and hematopoietic complications that limit quality of life following chemotherapy (CTX), yet the mechanisms underlying these defects remain incompletely understood. Using a murine model of doxorubicin (DOX)-based leukemia induction therapy, we show that CTX induces inflammatory remodeling of the bone marrow (BM) niche. DOX treatment resulted in loss of arteriolar vasculature, blockade of mesenchymal stromal cell (MSC) differentiation, trabecular bone loss, and reduced niche capacity to maintain hematopoietic stem cells (HSCs). These defects were accompanied by aberrant immune activation within the BM, marked by increased interferon-γ (IFNγ) production by CD8⁺ T cells. Inhibition of IFNγ signaling partially restored arteriolar vessels and adipogenic differentiation. Moreover, combined IFNγ blockade and deferoxamine mesylate (DFM), which promotes vascular recovery, attenuated chemotherapy-associated skeletal damage. Consistent with these findings, paired BM samples collected at diagnosis and post-CTX from leukemia patients exhibited altered MSC lineage priming, upregulation of inflammatory pathways, and expansion of BM CD8⁺ memory T cells after treatment. Together, these findings implicate IFNγ-driven chronic inflammatory remodeling as a central mechanism of CTX-associated BM niche dysfunction and pinpoints inflammatory signaling as a potential target to preserve BM function and long-term tissue integrity.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S2 shows validation of sgRNA -mediated knockout of hit RBPs, comparison of hit RBP depletion in RN2c in vitro versus in vivo, effects of ELAVL1 loss on human AML cell lines, characteristics of the MLL-AF9 AML mouse model, and ELAVL1 expression in normal hematopoietic cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S2 shows validation of sgRNA -mediated knockout of hit RBPs, comparison of hit RBP depletion in RN2c in vitro versus in vivo, effects of ELAVL1 loss on human AML cell lines, characteristics of the MLL-AF9 AML mouse model, and ELAVL1 expression in normal hematopoietic cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Table S1 shows expression of RBPs in an RNA-sequencing data set of human bone marrow hematopoietic stem and progenitor subpopulations.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Table S1 shows expression of RBPs in an RNA-sequencing data set of human bone marrow hematopoietic stem and progenitor subpopulations.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Table S2 shows sequences of (a) sgRNAs from the RBP screen, (b) sequencing primers, (c) shRNAs and human-targeting sgRNAs, (d) eCLIP oligos.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Table S2 shows sequences of (a) sgRNAs from the RBP screen, (b) sequencing primers, (c) shRNAs and human-targeting sgRNAs, (d) eCLIP oligos.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Table S9 shows the (a) differentially expressed transcripts and (b) altered pathways as identified by GSEA from the ELAVL1 knockdown human primary AML RNA-sequencing data set.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Table S9 shows the (a) differentially expressed transcripts and (b) altered pathways as identified by GSEA from the ELAVL1 knockdown human primary AML RNA-sequencing data set.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S4 shows the validation of ELAVL1 knockdown by western blot and effects of ELAVL1 loss on human primary AML cells in vitro and in vivo.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S4 shows the validation of ELAVL1 knockdown by western blot and effects of ELAVL1 loss on human primary AML cells in vitro and in vivo.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S5 shows the effects of DHTS treatment on THP-1 and human primary AML cells in vitro, the effects of MS-444 treatment on human umbilical cord blood in vivo, and validation of ELAVL1 overexpression by western blot.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S5 shows the effects of DHTS treatment on THP-1 and human primary AML cells in vitro, the effects of MS-444 treatment on human umbilical cord blood in vivo, and validation of ELAVL1 overexpression by western blot.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S7 shows the expression profile of TOMM34 in normal human bone marrow and across different AML and CML data sets. The effects of TOMM34 depletion on human primary AML cells in vitro and validation of TOMM34 knockdown and overexpression is shown.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S7 shows the expression profile of TOMM34 in normal human bone marrow and across different AML and CML data sets. The effects of TOMM34 depletion on human primary AML cells in vitro and validation of TOMM34 knockdown and overexpression is shown.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S3 shows the generation of the bcCML mouse model and the effects of ELAVL1 on normal bone marrow in vivo.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Supplemental Figure S3 shows the generation of the bcCML mouse model and the effects of ELAVL1 on normal bone marrow in vivo.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Table S5 shows the log2 fold change of differentially expressed transcripts from the ELAVL1 knockout RN2c RNA-sequencing data set.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
Table S5 shows the log2 fold change of differentially expressed transcripts from the ELAVL1 knockout RN2c RNA-sequencing data set.